全文获取类型
收费全文 | 191478篇 |
免费 | 35266篇 |
国内免费 | 2796篇 |
学科分类
医药卫生 | 229540篇 |
出版年
2023年 | 5081篇 |
2022年 | 1605篇 |
2021年 | 4479篇 |
2020年 | 6947篇 |
2019年 | 3348篇 |
2018年 | 8727篇 |
2017年 | 8342篇 |
2016年 | 9607篇 |
2015年 | 9719篇 |
2014年 | 17223篇 |
2013年 | 17834篇 |
2012年 | 8589篇 |
2011年 | 8538篇 |
2010年 | 12169篇 |
2009年 | 15757篇 |
2008年 | 7948篇 |
2007年 | 6157篇 |
2006年 | 8558篇 |
2005年 | 5456篇 |
2004年 | 4680篇 |
2003年 | 3455篇 |
2002年 | 3280篇 |
2001年 | 4755篇 |
2000年 | 4021篇 |
1999年 | 4022篇 |
1998年 | 3967篇 |
1997年 | 3629篇 |
1996年 | 3578篇 |
1995年 | 3444篇 |
1994年 | 2131篇 |
1993年 | 1730篇 |
1992年 | 1891篇 |
1991年 | 1876篇 |
1990年 | 1532篇 |
1989年 | 1600篇 |
1988年 | 1409篇 |
1987年 | 1225篇 |
1986年 | 1252篇 |
1985年 | 1053篇 |
1984年 | 829篇 |
1983年 | 748篇 |
1982年 | 657篇 |
1981年 | 496篇 |
1980年 | 470篇 |
1979年 | 553篇 |
1978年 | 491篇 |
1977年 | 585篇 |
1975年 | 454篇 |
1974年 | 427篇 |
1972年 | 463篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
Purnima Gogoi Geetika Kaur Nikhlesh K Singh 《World journal of gastroenterology : WJG》2022,28(46):6497-6511
Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related mortality in the United States. Across the globe, people in the age group older than 50 are at a higher risk of CRC. Genetic and environmental risk factors play a significant role in the development of CRC. If detected early, CRC is preventable and treatable. Currently, available screening methods and therapies for CRC treatment reduce the incidence rate among the population, but the micrometastasis of cancer may lead to recurrence. Therefore, the challenge is to develop an alternative therapy to overcome this complication. Nanotechnology plays a vital role in cancer treatment and offers targeted chemotherapies directly and selectively to cancer cells, with enhanced therapeutic efficacy. Additionally, nanotechnology elevates the chances of patient survival in comparison to traditional chemotherapies. The potential of nanoparticles includes that they may be used simultaneously for diagnosis and treatment. These exciting properties of nanoparticles have enticed researchers worldwide to unveil their use in early CRC detection and as effective treatment. This review discusses contemporary methods of CRC screening and therapies for CRC treatment, while the primary focus is on the theranostic approach of nanotechnology in CRC treatment and its prospects. In addition, this review aims to provide knowledge on the advancement of nanotechnology in CRC and as a starting point for researchers to think about new therapeutic approaches using nanotechnology. 相似文献
4.
5.
6.
7.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
8.
9.
10.